|
40 Companies |
|
51 Products |
|
51 Products |
|
0 Mechanisms of Action |
|
20 Trials |
|
425 News |
|
| «12345678» |
- | acetylcysteine solution / Generic mfg.
Enrollment closed: N-Acetylcysteine in Patients With Sickle Cell Disease (clinicaltrials.gov) - Feb 2, 2016
P3, N=96, Active, not recruiting, Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Recruiting --> Active, not recruiting
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Trial primary completion date: Bone Marrow Transplantation in Young Adults With Severe Sickle Cell Disease (clinicaltrials.gov) - Jan 28, 2016
P2, N=15, Active, not recruiting, Sponsor: Emory University
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2015 --> Dec 2017
- hydroxyurea / Generic mfg.
Trial completion, Adherence: Hydroxyurea Adherence for Personal Best in Sickle Cell Treatment: HABIT (clinicaltrials.gov) - Jan 27, 2016
P2, N=60, Completed, Sponsor: Columbia University
Trial primary completion date: Dec 2015 --> Dec 2017 Recruiting --> Completed
- Enrollment change: Use of Mobile Technology for Intensive Training in Medication Management (clinicaltrials.gov) - Jan 21, 2016
P=N/A, N=50, Recruiting, Sponsor: Duke University
Recruiting --> Completed N=25 --> 50
- Enrollment change, Trial suspension: Fertility Preservation in Women Who Will Have Gonadotoxic Therapy or Hematopoetic Stem Cell Transplantation, and in Women With Sickle Cell Disease (clinicaltrials.gov) - Dec 22, 2015
P=N/A, N=10, Suspended, Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
N=25 --> 50 N=50 --> 10 | Recruiting --> Suspended
- Trial suspension: Study of Beet Juice for Patients With Sickle Cell Anemia (clinicaltrials.gov) - Dec 5, 2015
P2, N=24, Suspended, Sponsor: Daniel Kim-Shapiro
N=50 --> 10 | Recruiting --> Suspended Recruiting --> Suspended
- Trial completion: DREPAGREFFE: Allogeneic Genoidentical Stem Cell Transplantation in Children With Sickle-cell Anemia and Cerebral Vasculopathy (clinicaltrials.gov) - Dec 5, 2015
P=N/A, N=63, Completed, Sponsor: Assistance Publique - H
Recruiting --> Suspended Active, not recruiting --> Completed
- Trial completion: KNOW-IT: Improving Disease Knowledge in Adolescents With Sickle Cell Disease (clinicaltrials.gov) - Dec 4, 2015
P=N/A, N=150, Completed, Sponsor: The University of The West Indies
Active, not recruiting --> Completed Active, not recruiting --> Completed
- plerixafor / Generic mfg.
Trial initiation date, Trial primary completion date: DrepaMob: Assessment of Tolerance of Mobilizing Peripheral Hematopoietic Stem Cells by Plerixafor in Sickle Cell Patients (clinicaltrials.gov) - Dec 4, 2015
P1/2, N=5, Not yet recruiting, Sponsor: Assistance Publique - H
Active, not recruiting --> Completed Initiation date: May 2015 --> Dec 2015 | Trial primary completion date: Sep 2017 --> Apr 2018
- losartan / Generic mfg.
Enrollment closed: Losartan for Sickle Cell Kidney Disease (clinicaltrials.gov) - Nov 17, 2015
P=N/A, N=40, Active, not recruiting, Sponsor: Emory University
Initiation date: May 2015 --> Dec 2015 | Trial primary completion date: Sep 2017 --> Apr 2018 Recruiting --> Active, not recruiting
- | ledipasvir/sofosbuvir / Generic mfg.
Enrollment closed: Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 or 24 Weeks in Genotype 1 or 4 HCV Infected Adults With Sickle Cell Disease (clinicaltrials.gov) - Nov 6, 2015
P2, N=25, Active, not recruiting, Sponsor: Gilead Sciences
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ticagrelor / Generic mfg.
Trial suspension: HESTIA 1: A Pharmacokinetic (PK) and Pharmacodynamic (PD) Dose-ranging Phase II Study of Ticagrelor in Paediatric Patients With Sickle Cell Disease (clinicaltrials.gov) - Oct 22, 2015
P2, N=39, Suspended, Sponsor: AstraZeneca
Recruiting --> Active, not recruiting Recruiting --> Suspended
- Trial completion, Trial primary completion date: Hepcidin Levels in Sickle Cell Disease (SCD) (clinicaltrials.gov) - Oct 8, 2015
P=N/A, N=42, Completed, Sponsor: Kenneth Ataga, MD
Recruiting --> Suspended Enrolling by invitation --> Completed | Trial primary completion date: May 2015 --> Sep 2015
- Zolinza (vorinostat) / Merck (MSD)
Trial completion: Efficacy of Vorinostat to Induce Fetal Hemoglobin in Sickle Cell Disease (clinicaltrials.gov) - Oct 8, 2015
P2, N=5, Completed, Sponsor: Dana-Farber Cancer Institute
Enrolling by invitation --> Completed | Trial primary completion date: May 2015 --> Sep 2015 Active, not recruiting --> Completed
- || PF-04447943 / Pfizer
Trial primary completion date: Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Study Of PF-04447943, Co-Administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease (clinicaltrials.gov) - Oct 7, 2015
P1, N=64, Recruiting, Sponsor: Pfizer
Active, not recruiting --> Completed Trial primary completion date: Feb 2016 --> Jul 2016
- morphine sulphate / Generic mfg., hydromorphone hydrochloride / Generic mfg.
Enrollment open: Comparing Acute Pain Management Protocols for Patients With Sickle Cell Disease (clinicaltrials.gov) - Oct 2, 2015
P4, N=77, Recruiting, Sponsor: Duke University
Trial primary completion date: Feb 2016 --> Jul 2016 Not yet recruiting --> Recruiting
- Trial primary completion date: Evaluation of Nocturnal Enuresis and Barriers to Treatment Among Pediatric Patients With Sickle Cell Disease (clinicaltrials.gov) - Oct 1, 2015
P=N/A, N=250, Recruiting, Sponsor: St. Jude Children's Research Hospital
Not yet recruiting --> Recruiting Trial primary completion date: Oct 2015 --> Apr 2016
- hydroxyurea / Generic mfg.
Trial primary completion date: State Of The Art Functional Imaging In Sickle Cell Disease (clinicaltrials.gov) - Oct 1, 2015
P=N/A, N=60, Recruiting, Sponsor: St. Jude Children's Research Hospital
Trial primary completion date: Oct 2015 --> Apr 2016 Trial primary completion date: Dec 2015 --> Jun 2016
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Enrollment closed, Trial primary completion date: Bone Marrow Transplantation in Young Adults With Severe Sickle Cell Disease (clinicaltrials.gov) - Sep 22, 2015
P2, N=15, Active, not recruiting, Sponsor: Emory University
Trial primary completion date: Dec 2015 --> Jun 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2015 --> Dec 2015
- Trial completion, Enrollment change, Trial primary completion date: Topical Sodium Nitrite for Chronic Leg Ulcers in Adult Patients With Blood Disorders (clinicaltrials.gov) - Sep 22, 2015
P1, N=28, Completed, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2015 --> Dec 2015 Recruiting --> Completed | N=44 --> 28 | Trial primary completion date: Apr 2016 --> Sep 2015
- Enrollment open, Enrollment change, Trial primary completion date: Molecular Phenotyping of Asthma in Sickle Cell Disease (clinicaltrials.gov) - Sep 14, 2015
P=N/A, N=100, Recruiting, Sponsor: Nemours Children's Clinic
Recruiting --> Completed | N=44 --> 28 | Trial primary completion date: Apr 2016 --> Sep 2015 Completed --> Recruiting | N=75 --> 100 | Trial primary completion date: Sep 2014 --> Sep 2016
- Trial completion, Enrollment change, Trial primary completion date: Iron Overload and Growth Velocity in Thalassemia and Sickle Cell Anemia (clinicaltrials.gov) - Sep 1, 2015
P=N/A, N=93, Completed, Sponsor: HaEmek Medical Center, Israel
Completed --> Recruiting | N=75 --> 100 | Trial primary completion date: Sep 2014 --> Sep 2016 Recruiting --> Completed | N=150 --> 93 | Trial primary completion date: Dec 2014 --> Dec 2010
- Trial completion, Enrollment change, Trial primary completion date: Clinical Diagnosis of Teenagers Admitted to Pediatric Departments (clinicaltrials.gov) - Sep 1, 2015
P=N/A, N=1389, Completed, Sponsor: HaEmek Medical Center, Israel
Recruiting --> Completed | N=150 --> 93 | Trial primary completion date: Dec 2014 --> Dec 2010 Active, not recruiting --> Completed | N=5000 --> 1389 | Trial primary completion date: Dec 2013 --> May 2010
- Trial completion, Enrollment change, Trial primary completion date: Sickle Cell Anemia Screening and Prevention in Northern Israel (clinicaltrials.gov) - Sep 1, 2015
P=N/A, N=69, Completed, Sponsor: HaEmek Medical Center, Israel
Active, not recruiting --> Completed | N=5000 --> 1389 | Trial primary completion date: Dec 2013 --> May 2010 Recruiting --> Completed | N=100000 --> 69 | Trial primary completion date: Dec 2014 --> Mar 2009
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Trial primary completion date: Non-Myeloablative Bone Marrow Transplant for Patients With Sickle Cell Anemia and Other Blood Disorders (clinicaltrials.gov) - Aug 14, 2015
P2, N=50, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Recruiting --> Completed | N=100000 --> 69 | Trial primary completion date: Dec 2014 --> Mar 2009 Trial primary completion date: May 2016 --> May 2017
- Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Trial primary completion date: A Phase II Trial of Regadenoson in Sickle Cell Anemia (clinicaltrials.gov) - Aug 13, 2015
P2, N=96, Recruiting, Sponsor: Dana-Farber Cancer Institute
Trial primary completion date: May 2016 --> May 2017 Trial primary completion date: Apr 2015 --> Jun 2016
- Enrollment closed: iTransition: Patient-Provider Tools to Improve the Transition to Adult Care in Sickle Cell Disease (clinicaltrials.gov) - Aug 5, 2015
P=N/A, N=85, Active, not recruiting, Sponsor: Children's Hospital Medical Center, Cincinnati
Trial primary completion date: Apr 2015 --> Jun 2016 Enrolling by invitation --> Active, not recruiting
- Enrollment change: Fertility Preservation in Women Who Will Have Gonadotoxic Therapy or Hematopoetic Stem Cell Transplantation, and in Women With Sickle Cell Disease (clinicaltrials.gov) - Aug 5, 2015
P=N/A, N=50, Recruiting, Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Enrolling by invitation --> Active, not recruiting N=10 --> 50
- ledipasvir/sofosbuvir / Generic mfg.
Trial primary completion date: Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 or 24 Weeks in Genotype 1 or 4 HCV Infected Adults With Sickle Cell Disease (clinicaltrials.gov) - Jul 1, 2015
P2, N=25, Recruiting, Sponsor: Gilead Sciences
N=10 --> 50 Trial primary completion date: Dec 2015 --> Jun 2016
- Trial primary completion date: Study of Decitabine and Tetrahydrouridine (THU) in Patients With Sickle Cell Disease (clinicaltrials.gov) - Jun 30, 2015
P1, N=25, Recruiting, Sponsor: The Cleveland Clinic
Trial primary completion date: Dec 2015 --> Jun 2016 Trial primary completion date: Dec 2014 --> Dec 2015
- decitabine / Generic mfg.
Enrollment change, Trial suspension: Decitabine for High-Risk Sickle Cell Disease (clinicaltrials.gov) - Jun 29, 2015
P2, N=10, Suspended, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Trial primary completion date: Dec 2014 --> Dec 2015 N=40 --> 10 | Recruiting --> Suspended
- | NKTT120 / NKT Therap
Trial completion: Safety, Pharmacokinetic, and Pharmacodynamic Study of NKTT120 in Adult Patients With Stable Sickle Cell Disease (SCD) (clinicaltrials.gov) - Jun 26, 2015
P1, N=21, Completed, Sponsor: NKT Therapeutics
N=40 --> 10 | Recruiting --> Suspended Active, not recruiting --> Completed
- hydroxyurea / Generic mfg.
Enrollment change, Trial termination, Trial primary completion date: Risk-based Therapy for Sickle Cell Anemia: A Feasibility Study (clinicaltrials.gov) - Jun 22, 2015
P2, N=10, Terminated, Sponsor: Children's Research Institute
Active, not recruiting --> Completed N=48 --> 10 | Recruiting --> Terminated | Trial primary completion date: Dec 2016 --> Jun 2015; Participant withdrew consent
- Trial completion, Trial primary completion date: RAND: Albuminuria Reduction With Renin Angiotensin System Inhibitors in SCA Patients (clinicaltrials.gov) - Jun 18, 2015
P=N/A, N=53, Completed, Sponsor: Assistance Publique - H
N=48 --> 10 | Recruiting --> Terminated | Trial primary completion date: Dec 2016 --> Jun 2015; Participant withdrew consent Active, not recruiting --> Completed | Trial primary completion date: Jun 2014 --> Sep 2014
- Trial completion: The Brigance Assessment Of Individual Neurodevelopment In Young Children With Sickle Cell Disease- 2 (clinicaltrials.gov) - Jun 16, 2015
P=N/A, N=248, Completed, Sponsor: St. Jude Children's Research Hospital
Active, not recruiting --> Completed | Trial primary completion date: Jun 2014 --> Sep 2014 Active, not recruiting --> Completed
- Trial primary completion date: Study of Beet Juice for Patients With Sickle Cell Anemia (clinicaltrials.gov) - Jun 11, 2015
P2, N=24, Recruiting, Sponsor: Daniel Kim-Shapiro
Active, not recruiting --> Completed Trial primary completion date: Feb 2015 --> Feb 2017
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Trial primary completion date: Bone Marrow Transplantation in Young Adults With Severe Sickle Cell Disease (clinicaltrials.gov) - Jun 11, 2015
P2, N=15, Recruiting, Sponsor: Emory University
Trial primary completion date: Feb 2015 --> Feb 2017 Trial primary completion date: May 2015 --> Aug 2015
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Trial primary completion date: A Reduced Toxicity Allogeneic Unrelated Donor Stem Cell Transplantation (SCT) for Severe Sickle Cell Disease (clinicaltrials.gov) - Jun 11, 2015
P2, N=25, Suspended, Sponsor: Nationwide Children's Hospital
Trial primary completion date: May 2015 --> Aug 2015 Trial primary completion date: Jan 2014 --> Jan 2016
- Trial primary completion date: High-Tc Susceptometer to Monitor Transfusional Iron Overload (clinicaltrials.gov) - Jun 11, 2015
P2, N=190, Recruiting, Sponsor: Columbia University
Trial primary completion date: Jan 2014 --> Jan 2016 Trial primary completion date: Mar 2015 --> Jun 2016
- Enrollment change, Trial withdrawal: Study of Blood Platelets in Sickle Cell Disease (clinicaltrials.gov) - Jun 9, 2015
P=N/A, N=0, Withdrawn, Sponsor: Rockefeller University
Trial primary completion date: Mar 2015 --> Jun 2016 N=90 --> 0 | Suspended --> Withdrawn
- Trial completion, Enrollment change, Trial primary completion date, Immunomodulating: Fresh Versus Old Red Blood Cells for Transfusion (clinicaltrials.gov) - Jun 3, 2015
P=N/A, N=14, Completed, Sponsor: Columbia University
N=90 --> 0 | Suspended --> Withdrawn Active, not recruiting --> Completed | N=22 --> 14 | Trial primary completion date: Mar 2011 --> Oct 2010
- Trial completion, Enrollment change, Adherence: Medication Adherence in Youth With Sickle Cell Disease (SCD) (clinicaltrials.gov) - May 27, 2015
P=N/A, N=36, Completed, Sponsor: St. Jude Children's Research Hospital
Active, not recruiting --> Completed | N=22 --> 14 | Trial primary completion date: Mar 2011 --> Oct 2010 Recruiting --> Completed | N=60 --> 36
- Trial completion: Effectiveness of a Computerized Tool (PAINRelieveIt) to Help Manage Pain Related to Sickle Cell Disease (clinicaltrials.gov) - May 27, 2015
P=N/A, N=279, Completed, Sponsor: University of Illinois at Chicago
Recruiting --> Completed | N=60 --> 36 Active, not recruiting --> Completed
- Enrollment change, Trial termination: Effects of Transfusion of Older Stored Red Cells (clinicaltrials.gov) - May 19, 2015
P=N/A, N=3, Terminated, Sponsor: Columbia University
Active, not recruiting --> Completed N=60 --> 3 | Recruiting --> Terminated; Difficulty recruiting donors and recipients, looking for alternative sites
- Trial termination, Trial primary completion date: RESCUED: Regional Anesthesia for Sickle Cell Crisis Using Ultrasound in The Emergency Department: Phase I (clinicaltrials.gov) - May 2, 2015
P1, N=2, Terminated, Sponsor: Mount Sinai School of Medicine
N=60 --> 3 | Recruiting --> Terminated; Difficulty recruiting donors and recipients, looking for alternative sites Recruiting --> Terminated | Trial primary completion date: Jan 2014 --> Aug 2013; lack of resources
- methylphenidate tablet / Generic mfg.
Enrollment change: Ameliorating Attention Problems in Children With Sickle Cell Disease (SCD) (clinicaltrials.gov) - Apr 30, 2015
P3, N=34, Completed, Sponsor: Temple University
Recruiting --> Terminated | Trial primary completion date: Jan 2014 --> Aug 2013; lack of resources N=60 --> 34
- Clotinab (abciximab) / ISU Abxis
Enrollment change, Trial withdrawal, Trial primary completion date: Abciximab (ReoPro) as a Therapeutic Intervention for Sickle Cell Vaso-Occlusive Pain Crisis (clinicaltrials.gov) - Apr 19, 2015
P2, N=0, Withdrawn, Sponsor: St. Louis University
N=60 --> 34 N=100 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Mar 2016 --> Mar 2015
- budesonide inhalation suspension / Generic mfg.
Trial primary completion date: Inhaled Corticosteroid Use to Prevent Acute Chest Syndrome Recurrence in Children Between 1 and 4 With Sickle Cell Disease: a Feasibility Trial (clinicaltrials.gov) - Apr 18, 2015
P1, N=20, Recruiting, Sponsor: Vanderbilt University
N=100 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Mar 2016 --> Mar 2015 Trial primary completion date: Nov 2015 --> Sep 2016
- plerixafor / Generic mfg.
Trial initiation date, Trial primary completion date: DrepaMob: Assessment of Tolerance of Mobilizing Peripheral Hematopoietic Stem Cells by Plerixafor in Sickle Cell Patients (clinicaltrials.gov) - Apr 14, 2015
P1/2, N=5, Not yet recruiting, Sponsor: Assistance Publique - H
Trial primary completion date: Nov 2015 --> Sep 2016 Initiation date: Sep 2014 --> May 2015 | Trial primary completion date: Mar 2017 --> Sep 2017
- NKTT120 / NKT Therap
Trial primary completion date: Safety, Pharmacokinetic, and Pharmacodynamic Study of NKTT120 in Adult Patients With Stable Sickle Cell Disease (SCD) (clinicaltrials.gov) - Apr 14, 2015
P1, N=21, Active, not recruiting, Sponsor: NKT Therapeutics
Initiation date: Sep 2014 --> May 2015 | Trial primary completion date: Mar 2017 --> Sep 2017 Trial primary completion date: Dec 2014 --> May 2015